Oral Ritlecitinib and Brepocitinib for Moderate-to-Severe Ulcerative Colitis: Results From a Randomized, Phase 2b Study

This publication has 32 references indexed in Scilit:

• Erratum: The emerging safety profile of JAK inhibitors in rheumatic disease
  Nature Reviews Rheumatology, 2017
• Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition
  ACS Chemical Biology, 2016
• Type I interferons in infectious disease
  Nature Reviews Immunology, 2015
• T-Cell Signaling Regulated by the Tec Family Kinase, Itk
  Cold Spring Harbor Perspectives in Biology, 2010
• A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis
  Gastroenterology, 2007
• Test‐Based Exact Confidence Intervals for the Difference of Two Binomial Proportions
  Biometrics, 1999
• Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease
  Gastroenterology, 1994
• Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis
  New England Journal of Medicine, 1987
• Refining binomial confidence intervals
  Canadian Journal of Statistics, 1986
• Binomial Confidence Intervals
  Journal of the American Statistical Association, 1983